Ownership history in Rangeley Capital, LLC · 5 quarters on record
This page tracks every 13F SEC filing in which Rangeley Capital, LLC reported a position in ARBUTUS BIOPHARMA CORP (ABUS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 840,000 | — | 0% | 3.36% | $4.0M | $4.81 |
| 2025 Q3 | REDUCED | 840,000 | -25,000 | -2.9% | 3.30% | $3.8M | $4.54 |
| 2025 Q2 | REDUCED | 865,000 | -484,000 | -35.9% | 3.19% | $2.7M | $3.09 |
| 2025 Q1 | REDUCED | 1,349,000 | -110,000 | -7.5% | 5.04% | $4.7M | $3.49 |
| 2024 Q4 | INITIATED | 1,459,000 | — | — | 4.28% | $4.8M | $3.27 |
As of 2025 Q4 — sorted by position size